Capromab pendetide
Capromab pendetide was approved by the U.S. Food and Drug Administration (FDA) on October 28, 1996. It was developed and marketed as ProstaScint® by Cytogen (a member of EUSA Pharma).
Capromab pendetide is a murine monoclonal antibody, which is directed against a glycoprotein expressed by prostate epithelium known as Prostate Specific Membrane Antigen (PSMA). It is indicated as a diagnostic imaging agent in newly-diagnosed patients with biopsy-proven prostate cancer.
ProstaScint® is available as a kit for intravenous use, containing 0.5 mg/mL of Capromab pendetide. The recommended dose is 0.5 mg radiolabeled with 5 mCi of Indium In 111 chloride given over 5 minutes.
General Information
Update Date：2015-10-14
- Drug Name：
- Capromab pendetide
- Research Code：
- CYT-356
- Trade Name：
- ProstaScint®
- MOA：
- PSMA-targeting and In 111 accumulation
- Indication：
- Diagnostic agents
- Status：
- Approved
- Company：
- Cytogen (Originator), EUSA Pharma (Originator)
- Sales：
- ATC Code：
- V09IB04
Approved Countries or Area
Update Date：2015-07-29
| Approval Date | Approval Type | Trade Name | Indication | Dosage Form | Strength | Company | Review Classification |
|---|---|---|---|---|---|---|---|
| 1996-10-28 | Marketing approval | ProstaScint | Prostate cancer | Injection | 0.5 mg/mL | EUSA Pharma |
Biology Structure
Update Date：2015-07-29
| Type | Whole antibody |
|
| Source | Murine | |
| Molecular Formula | ||
| Molecular Weight | ||
| CAS No. | 145464-28-4 | |
| Expression System | Mammalian Cell |